Blueprint Medicines (NASDAQ:BPMC)

CAPS Rating: 5 out of 5

Caps

How do you think BPMC will perform against the market?

Add Stock to CAPS Watchlist

All Players

24 Outperform
1 Underperform
 

All-Star Players

12 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top BPMC Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

BPMC VS S&P 500 (SPY)

BPMC Summary

Fools bullish on BPMC are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about BPMC.

Recs

0
Member Avatar TMFEBCapital (79.41) Submitted: 6/1/2018 10:50:57 AM : Outperform Start Price: $83.99 BPMC Score: -21.99

The company faces stiff competition from LOXO in developing RET targeting cancer treatment and LOXO has the pole position at ASCO over the coming days because of an oral presentation it's making. That could weigh down BPMC shares in the short-term, but this company's RET data is also compelling. Additionally, its CEO is the former President of Algeta -- a company that developed Xofigo and was sold to Bayer. With proven management and a good shot at a game-changing approach to medicine, I think this one will be a one-time winner, despite the risk of a short-term drop.

Recs

0
Member Avatar CMFBLSH (88.48) Submitted: 1/26/2018 11:34:35 AM : Outperform Start Price: $68.55 BPMC Score: -9.11

BLU-285's value supports entire EV of company right now (@ low $80's). It is a "miracle drug" in systemic mastocytosis and seems to work in well in some gastrointestinal stromal tumors (GIST). They have a huge library of kinases and the ability to modify them to reduce off-target interactions that cause toxicity issues. They may be the best. Success outside of BLU-285 is icing on the cake.

Another drug they have coming is BLU-667 that addresses a mutation called RET which is a driver of many cancers. LOXO has one too. But the RET market is very big to support two, especially if there is differentiation. May get some information on that at AACR in April or ASCO in June.

In a year or so, stock could be $150-200. Current: $83.83.

Leaderboard

Find the members with the highest scoring picks in BPMC.

Score Leader

HDTVBG

HDTVBG (< 20) Score: +245.78

The Score Leader is the player with the highest score across all their picks in BPMC.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
km00nster < 20 6/26/2015 Outperform 5Y $27.96 +156.60% +39.60% +117.00 0 Comment
gunterle 67.32 1/24/2017 Outperform 5Y $32.28 +122.26% +28.89% +93.37 0 Comment
jettyjett 57.49 5/30/2017 Outperform 5Y $35.50 +102.10% +21.52% +80.58 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. efarev 98.62 5/23/2017 Outperform 5Y $39.00 +83.96% +22.34% +61.62 0 Comment
AppleMoonbeam < 20 7/25/2017 Outperform 5Y $55.18 +30.03% +18.58% +11.46 0 Comment
HDTVBG < 20 9/17/2018 Underperform 3W $73.95 -2.98% +0.95% +3.93 0 Comment
Plasmidologist 31.34 8/8/2018 Outperform 5Y $70.00 +2.49% +2.94% -0.45 0 Comment
sublimeinvestor 30.18 8/8/2018 Outperform 5Y $70.00 +2.49% +3.00% -0.51 0 Comment
bthym 59.27 8/3/2018 Outperform 5Y $69.68 +2.96% +3.91% -0.94 0 Comment
mrbill6 < 20 9/4/2018 Outperform 3M $76.25 -5.91% +1.29% -7.20 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for BPMC.

Featured Broker Partners


Advertisement